The inverse correlation between BDNF and inflammation markers and the increased BDNF in the MCP group supported by the results of this study show that MCP may be an essential potential agent for use in the treatment of Alzheimer’s disease. This evidence concerns the gene BDNF and early-onset autosomal dominant Alzheimer disease.